VVN001
/ VivaVision
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
November 20, 2024
VVN001-CCS-301: Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
(clinicaltrials.gov)
- P3 | N=700 | Recruiting | Sponsor: VivaVision Biotech, Inc | Not yet recruiting ➔ Recruiting
Enrollment open • Dry Eye Disease • Ophthalmology
April 11, 2024
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
(clinicaltrials.gov)
- P3 | N=700 | Not yet recruiting | Sponsor: VivaVision Biotech, Inc
New P3 trial • Dry Eye Disease • Ophthalmology
December 13, 2023
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
(clinicaltrials.gov)
- P2 | N=169 | Completed | Sponsor: VivaVision Biotech, Inc | Phase classification: P2a ➔ P2
Phase classification • Dry Eye Disease • Ophthalmology
January 01, 2023
A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease.
(PubMed, Ocul Surf)
- "There were no major safety issues of note. Appropriately powered studies will be required with a priori selection of the efficacy endpoints to evaluate VVN001's therapeutic potential."
Journal • P2a data • Dry Eye Disease • Infectious Disease • Nephrology • Ophthalmology • Pain
August 26, 2022
PO103 - A Phase 2a, Double-Masked, Randomized, Vehicle-Controlled Trial of VVN001 in Subjects With DED
(AAO 2022)
- "Clinically and/or statistically significant dose-related improvement relative to vehicle were seen in corneal staining, Schirmer's Test and SANDE. Adverse event rates were low (≤ 14% mostly ocular) and no greater in active groups than in the vehicle group.ConclusionVVN-001 Ophthalmic solution may be a novel therapeutic for the treatment of dry eye disease."
Clinical • P2a data • Dry Eye Disease • Ophthalmology
February 02, 2022
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
(clinicaltrials.gov)
- P2a | N=169 | Completed | Sponsor: VivaVision Biotech, Inc | Active, not recruiting ➔ Completed
Trial completion • Dry Eye Disease • Ophthalmology
October 19, 2021
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
(clinicaltrials.gov)
- P2a; N=169; Active, not recruiting; Sponsor: VivaVision Biotech, Inc; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Dry Eye Disease • Ophthalmology
March 08, 2021
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
(clinicaltrials.gov)
- P2a; N=165; Recruiting; Sponsor: VivaVision Biotech, Inc; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Dry Eye Disease • Ocular Infections • Ophthalmology
November 19, 2020
The Protective Effects of VVN001 on LPS-Induced Inflammatory Responses in Human RPE Cells and in a Mouse Model of EIU.
(PubMed, Inflammation)
- "VVN001 alleviated the inflammatory response induced by LPS both in vitro and in vivo. The effect of anti-inflammation is associated with inhibiting the overproduction of ICAM-1 and blocking the activation of NLRP3 inflammasome and the NF-κB signaling pathway."
Journal • Complement-mediated Rare Disorders • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis • CXCL8 • ICAM1 • IL18 • IL6
September 19, 2020
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
(clinicaltrials.gov)
- P2a; N=165; Not yet recruiting; Sponsor: VivaVision Biotech, Inc
Clinical • New P2a trial • Dry Eye Disease • Ocular Infections • Ophthalmology
1 to 10
Of
10
Go to page
1